Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study

Author:

Bongaerts BrendaORCID,Arnold Suzanne V,Charbonnel Bernard H,Chen Hungta,Cooper Andrew,Fenici Peter,Gomes Marilia,Ji Linong,Khunti Kamlesh,Kosiborod Mikhail,Medina Jesús,Nicolucci Antonio,Shestakova Marina,Shimomura Iichiro,Tang Fengming,Watada Hirotaka,Rathmann WolfgangORCID

Abstract

IntroductionAlthough individualized target glycated hemoglobin (HbA1c) levels are recommended in older people with type 2 diabetes, studies report high levels of potential overtreatment. We aimed to investigate the proportion of older patients (aged ≥65 years) who potentially received an inappropriately intensive treatment (HbA1c level <7.0% (53.0 mmol/mol)) in a global study. Factors associated with intensive glycemic management and using glucose-lowering medications associated with a high risk of hypoglycemia (high-risk medications (insulin, sulfonylureas, and meglitinides)) were also assessed.Research design and methodsDISCOVER is a 3-year observational study program of 15 992 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. Data were collected at baseline (initiation of second-line therapy) and at 6, 12, and 24 months. Factors associated with an inappropriately intensive treatment or using high-risk medications were assessed using a hierarchical regression model.ResultsOf the 3344 older patients with baseline HbA1c data in our analytic cohort, 23.5% received inappropriate treatment intensification. Among those who had follow-up HbA1c data, 55.2%, 54.2%, and 53.5% were inappropriately tightly controlled at 6, 12, and 24 months, respectively, with higher proportions in high-income than in middle-income countries. The proportion of patients receiving high-risk medications was higher in middle-income countries than in high-income countries. Gross national income (per US$5000 increment) was associated with increased odds of inappropriately intensive treatment but with decreased odds of receiving high-risk medications.ConclusionsA large proportion of older DISCOVER patients received an inappropriately intensive glucose-lowering treatment across the 2 years of follow-up, with substantial regional variation. The use of high-risk medications in these patients is particularly concerning.

Funder

AstraZeneca

Publisher

BMJ

Subject

Endocrinology, Diabetes and Metabolism

Reference30 articles.

1. 12. Older Adults: Standards of Medical Care in Diabetes—2020

2. Chinese guidelines for type 2 diabetes prevention (2013);Chin J Diabetes,2014

3. International Diabetes Federation . Global guideline for type 2 diabetes. Available: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes.html [Accessed 31 Jan 2019].

4. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

5. AACE/ACE Comprehensive Diabetes Management Algorithm 2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3